Speech in Commons Chamber - Mon 22 Oct 2018
Paediatric Cancers of the Central Nervous System
"I congratulate my hon. Friend on his wonderful speech and pay tribute to Cian’s family for all they have done on this issue. Will he join me in paying tribute also to Cancer Research UK, which in the past 12 months has tripled its funding for brain cancer research, understanding …..."Ian Murray - View Speech
View all Ian Murray (Lab - Edinburgh South) contributions to the debate on: Paediatric Cancers of the Central Nervous System
Speech in Commons Chamber - Tue 08 May 2018
Oral Answers to Questions
"T1. If he will make a statement on his departmental responsibilities...."Ian Murray - View Speech
View all Ian Murray (Lab - Edinburgh South) contributions to the debate on: Oral Answers to Questions
Speech in Commons Chamber - Tue 08 May 2018
Oral Answers to Questions
"I am grateful to the Secretary of State for that update, but I would like to ask him about the Brexit transition agreement, which cuts the UK out of the European Medicines Agency. Can he give this House a cast-iron guarantee that that will not stop the regulation of new …..."Ian Murray - View Speech
View all Ian Murray (Lab - Edinburgh South) contributions to the debate on: Oral Answers to Questions
Written Question
Wednesday 18th April 2018
Asked by:
Ian Murray (Labour - Edinburgh South)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of eligible brain tumour patients with a glioblastoma had their tumour tissue assessed for MGMT promoter hypermethylation status between 1 January 2017 and 31 December 2017.
Answered by Steve Brine
This information is not held centrally.
Written Question
Wednesday 18th April 2018
Asked by:
Ian Murray (Labour - Edinburgh South)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of eligible brain tumour patients with a glioblastoma had their tumour tissue assessed for MGMT promoter hypermethylation status between 1 January 2016 and 31 December 2016.
Answered by Steve Brine
This information is not held centrally.
Written Question
Wednesday 18th April 2018
Asked by:
Ian Murray (Labour - Edinburgh South)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of eligible brain tumour patients with a glioma had their tumour tissue sample tested for 1p/19q co-deletion biomarker between 1 January 2017 and 31 December 2017.
Answered by Steve Brine
This information is not held centrally.
Written Question
Wednesday 18th April 2018
Asked by:
Ian Murray (Labour - Edinburgh South)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of eligible brain tumour patients with a glioma had their tumour tissue sample tested for 1p/19q co-deletion biomarker between 1 January 2016 and 31 December 2016.
Answered by Steve Brine
This information is not held centrally.
Written Question
Monday 5th February 2018
Asked by:
Ian Murray (Labour - Edinburgh South)
Question
to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when his Department's Task and Finish Working Group on Brain Tumour Research plans to publish its second report; and if he will make a statement.
Answered by Jackie Doyle-Price
The Task and Finish Working Group on Brain Tumour Research involves a wide range of people and organisations. The Working Group’s report was delivered to the Parliamentary under Secretary of State for Health (Lord O’Shaughnessy) on 31 January, and will be published as soon as possible.
Speech in Commons Chamber - Tue 14 Nov 2017
Diffuse Intrinsic Pontine Glioma
"I thank Mr Speaker for granting me this important Adjournment debate on diffuse intrinsic pontine glioma, a rare form of childhood brain tumour.
I applied for this debate to raise awareness of DIPG, to highlight the need for more research and development, to try to get better treatments and to …..."Ian Murray - View Speech
View all Ian Murray (Lab - Edinburgh South) contributions to the debate on: Diffuse Intrinsic Pontine Glioma
Speech in Commons Chamber - Tue 14 Nov 2017
Diffuse Intrinsic Pontine Glioma
"I thank the hon. Gentleman for his intervention. I shall come on to the subject of research and development. I have been in the House for seven years, and I live in hope of receiving a positive response from the Treasury Bench. Perhaps tonight we will get that far; indeed, …..."Ian Murray - View Speech
View all Ian Murray (Lab - Edinburgh South) contributions to the debate on: Diffuse Intrinsic Pontine Glioma